We previously reported a 53-year-old patient with multiple sclerosis showing acrocyanosis ([@B1]). She had multiple sclerosis at 34 years of age and began interferon-β (IFNB)-1b treatment at 42 years. She felt pain at the injection site at 52 years of age. Two months later, she frequently observed bending of the 30-gauge needle used for IFNB-1b injection. At 53 years of age, IFNB-1b treatment was switched to IFNB-1a because of injection site pain. Two months later, she developed acrocyanosis. Computed tomography revealed multiple subcutaneous high-density lesions at the previous injection sites in both thighs ([Picture A](#g001){ref-type="fig"}). X-rays and an ultrasound analysis showed multiple subcutaneous calcifications ([Picture B and C](#g001){ref-type="fig"}). The serum intact parathyroid hormone, calcium, phosphate, and interleukin-6 levels were normal upon discontinuing IFNB-1a. The serum antinuclear antibodies were increased by 160-fold. Lobular panniculitis was reported at the subcutaneous IFNB injection site ([@B2]). However, the precise calcification mechanism at the injection site has not been determined.
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